October 2025 in “Cosmetics” Genetic insights can lead to personalized treatments for acne, androgenetic alopecia, and alopecia areata.
October 2025 in “Brazilian Journal of Hair Health” Hair loss from weight-loss treatments is usually temporary and reversible.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
September 2025 in “JAAD Case Reports” Hair extensions can worsen scalp conditions and should be avoided in those with alopecia.
August 2025 in “Obstetrics and gynecology.” PCOS requires personalized treatment to manage symptoms and improve fertility and quality of life.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
August 2025 in “American Journal of Dermatopathology” Accurate diagnosis and personalized treatment are crucial in dermatopathology.
July 2025 in “Journal of Investigative Dermatology” Baricitinib stops hair loss and promotes regrowth in alopecia areata.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
Menopause-related skin changes may increase fungal infections and inflammation.
June 2025 in “Clinical and Experimental Dermatology” Baricitinib treatment led to dark brown hair regrowth in a red-haired woman with alopecia areata.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
May 2025 in “Frontiers in Pharmacology” New treatments are needed for non-scarring alopecia due to current limitations.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
May 2025 in “International Journal of Clinical Obstetrics and Gynaecology” A holistic approach, including lifestyle changes and surgery, is recommended for better long-term PCOS management.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
Baricitinib is more effective than methotrexate for severe alopecia areata.
March 2025 in “Meditsinskiy sovet = Medical Council” Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
February 2025 in “Diagnostics” Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.
February 2025 in “Expert Opinion on Drug Metabolism & Toxicology” Future alopecia treatments will improve with targeted therapies and personalized approaches.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
December 2024 in “Dermatological Reviews” New treatments for Alopecia Areata, like JAK inhibitors, are effective, and future research is exploring advanced therapies.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.